Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 116, Issue 5, Pages 696-711Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s12185-022-03412-x
Keywords
Polycythemia vera; Japan; Nationwide study; JAK2
Categories
Ask authors/readers for more resources
This study retrospectively analyzed the clinical characteristics of 596 Japanese patients with PV and found that the positive rates of JAK2 V617F and JAK2 exon 12 mutations were 94.3% and 2.1% respectively. The major causes of death were secondary malignancies, acute leukemia, non-leukemic progressive disease, and thrombotic and hemorrhagic complications. Thrombotic and hemorrhagic events occurred in 4.0% and 3.5% of patients during the clinical course. The international PV prognostic score was applicable to Japanese patients with PV.
The presence of a JAK2 V617F or JAK2 exon 12 mutation is one of the three major criteria listed for the diagnosis of polycythemia vera (PV) in the 2017 World Health Organization Classification. However, a nationwide study has not yet been conducted in Japan since the discovery of JAK2 mutations. Therefore, the Japanese Society of Hematology (JSH) retrospectively analyzed the clinical characteristics of 596 Japanese patients with PV diagnosed between April 2005 and March 2018. Among the 473 patients with complete data on JAK2 mutations available, 446 (94.3%) and 10 (2.1%) were positive for the JAK2 V617F and JAK2 exon 12 mutations, respectively. During a median follow-up of 46 months (range: 0-179 months), 47 (7.9%) deaths occurred. The major causes of death were secondary malignancies (23.4%), acute leukemia (12.8%), non-leukemic progressive disease (10.6%) and thrombotic (6.4%) and hemorrhagic complications (6.4%). Thrombotic and hemorrhagic events occurred during the clinical course in 4.0% (n = 24) and 3.5% (n = 21) of patients, respectively. These results show that the international PV prognostic score (age, venous thrombosis and leukocytosis) is applicable to Japanese patients with PV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available